Promab Biotechnologies

Promab Biotechnologies provides a completely comprehensive CAR-T pre-clinical package, allowing for accelerated proof-of-concept, and IP positioning, beginning with the generation of a mouse, rabbit, or human (library) monoclonal antibody, or with the synthesis and cloning of existing antibody sequence into a CAR expression construct. The generation of CAR-T cells, multi-platform, and high-throughput validation for enhanced cytotoxicity against the target antigen, and subsequent completion of pre-clinical animal models, demonstrating in vivo efficacy of your antibody and CAR-T cells, will position you to transition to the clinic. Promabis positioned to explore collaboration with partners in order to rapidly expand clinical targets.